Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LXR Biotech. -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (136)	1/11/1999 7:57:00 PM
From: BRAVEHEART	Respond to of 154

Dr. Topel joins LXR.... Hi Gang, This is another indication of where LXR is headed with it's product pipeline. Here is a link to the story: biz.yahoo.com This is a key development because Topel brings in a wealth of added R&D experience. Here is an excerpt from the story which sums this point up nicely. "Dr. Topol has served as principal investigator for more than 15 international multi-center clinical trials including trials that led to the approval of TPA (Genentech: Activase), a compound used to dissolve blood clots causing heart attack, and abciximab (Centocor and Eli Lilly: ReoPro), a compound used to prevent clot reformation in connection with treatment of heart attack. Activase and ReoPro are two of the most important cardiology drugs developed by the biotechnology industry." "Dr. Topol's primary focus on LXR's Cardiovascular Clinical Development Board will be to advise the Company on the preclinical and clinical development of Elirex™ and related compounds such as LXR1035, the Company's proprietary compounds for the protection of heart muscle cells in heart attack." PS: Technically we did not see much from this release primarily because of the technical indicators... : ( However I believe it is still a considerable development which will benefit shareholders long term. PATIENCE LONE WOLF